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Abstract
Background: In practice, it is difficult to compare the effectiveness of traditional antihypertensive treatment with
that of health promotion in reducing incidence rate of cardiovascular disease (IRCVD, events/year). This simulation
study compared the effectiveness of two approaches to reducing IRCVD in a sample population: a traditional
approach, in which high-risk patients are treated with conventional antihypertensive medications, and a
population-based approach, in which subjects participate in a health promotion program.
Methods: We constructed a simulation model for a sample population of middle-aged Japanese men whose
systolic blood pressure (SBP) levels are normally distributed (130 ± 20 mm Hg). The principal assumption was that
IRCVD increases exponentially according to SBP. The population IRCVD was calculated as the product of the
distribution of SBP multiplied by IRCVD at each SBP. The cumulative IRCVD was calculated by the definite integral
from the lowest to the highest SBP of IRCVD at each SBP level. The success rates were calculated according to SBP
and metabolic risk profiles in the two approaches, respectively.
Results: The reduction in IRCVD was twice as large for antihypertensive medications as it was for health promotion
in several situations. For example, if adherence to antihypertensive treatment occurred at a realistic level, the
decrease in IRCVD was estimated at 9.99 × 10
-4. In contrast, even if the health program was promoted optimistically,
the decrease in IRCVD was estimated at 4.69 × 10
-4.
Conclusions: The success rate-oriented simulation suggests that prescribing antihypertensive medications is
superior to promoting the health promotion program in reducing IRCVD in virtual middle-aged Japanese men.
Background
Metabolic syndrome is a significant risk factor for the
development of cardiovascular disease (CVD) in the
Japanese middle-aged population [1,2]. The Japanese
Ministry of Health, Labour and Welfare has recently
forced health insurance organizations to provide oppor-
tunities for their members to take annual health check
and health promotion programs to prevent and recover
from metabolic syndrome. Some epidemiologists who
support the government health and welfare policy insist
that a nationwide population-based approach has a
greater impact on the prevention of CVDs than does a
traditional approach in which antihypertensive medica-
tions are prescribed to high-risk patients (http://www.
niph.go.jp/soshiki/jinzai/koroshoshiryo/tokutei/) [3,4].
People who satisfy the Japanese criteria for metabolic
syndrome are advised to take the health promotion pro-
gram to decrease the effects of metabolic syndrome by
losing weight or reducing their waist circumference.
Public health nurses, with the assistance of dietitians,
exercise instructors, and occasionally regional primary
physicians and industrial physicians, supervise the
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any medium, provided the original work is properly cited.supporting dietary treatment and physical exercise of the
program. The guidelines of the health promotion
recommend patients with both metabolic syndrome and
hypertension to first consult their primary physician
and, after reducing their blood pressure (BP) to less
than 160/100 mm Hg, to take the health promotion pro-
gram separately [5,6]. In contrast, the Japanese Society
of Hypertension (JSH) 2009 hypertension treatment
guidelines insist that hypertensive subjects (BP > 140/90
mm Hg) with metabolic syndrome should visit primary
physicians before initiating the health promotion. As the
consequence of merging the two guidelines, the algo-
rithm is too complicated to be familiar to primary physi-
cians and members of health insurance organizations.
Moreover, in practice it is difficult to begin the two
approaches concurrently because most individuals are
willing to accept only one lifestyle change at a time [7].
Therefore, our concern is which should come first: tra-
ditional antihypertensive treatment, including estab-
lished lifestyle education, or vigorous lifestyle
interventions. Direct evidence is still lacking with regard
to the beneficial effects of lifestyle interventions (except
for smoking cessation) on cardiovascular events [8,9].
Epidemiological studies take several years and incur
huge costs to draw conclusions about whether the health
promotion program could substitute for traditional antihy-
pertensive medications in reducing cardiovascular events.
In a situation in which obvious clinical evidence is unavail-
able and extremely difficult, primary physicians have to
decide which procedure is suitable for an individual
patient with metabolic syndrome with hypertension: the
traditional antihypertensive treatment or the health pro-
motion program [3]. Simulation studies may offer patients
with hypertensive metabolic syndrome and their primary
physicians a possible course of action until clinical evi-
dence becomes available [10-12]. We aimed in this simula-
tion study to assess whether the Japanese health
promotion program for improving metabolic syndrome
has a large impact on the treatment of metabolic syn-
drome with hypertension. Should primary physicians post-
pone their prescriptions for antihypertensive medications,
even if their patients’ BP levels are higher than 140/90 mm
Hg? We calculated the anticipated reduction in the inci-
dence rate of CVD (IRCVD, events/year) that would follow
from conventional antihypertensive treatment and from
the newly introduced health promotion program in a
model population from the viewpoint of BP regulation.
Methods
Calculation of the IRCVD in a sample population
To simplify the simulation, we set a hypothetical sample
population. Systolic BP (SBP = x) was assumed to be
normally distributed and to represent the sum of the
risk factors for cardiovascular complications. In other
words, other risk factors, including metabolic profiles,
were transferred onto the SBP level. The predictive
value of metabolic syndrome for CVD is considerably
determined by that level [13,14]. The contribution of
metabolic factors to CVD is estimated as being much
smaller in Japan than in Western countries [15] because
the incidence of coronary heart disease in Japan is
approximately 1/3 of that in Western countries [5]. In
the model population, the mean (μ) and the standard
deviation (s) of the SBP levels were hypothesized to be
130 and 20 mm Hg, respectively, which were consistent
with those of Japanese male subjects at 60 years of age
[16]. The probability density function equals [17]
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Earlier epidemiological data suggested that the slope of
the curve on the scattergram for the relationship between
SBP and IRCVD was exponential [5]. IRCVD was assumed
by the following equation and based on the hypertension
guidelines and epidemiological data [16,18,19]: IRCVD =
Px
l
xm
k
( ) exp    
1 , where k, l, and m are constants
and represent the slope of the exponential curves, the
absolute value of IRCVD, and the rising point from e
0 =1 ,
and where simulations were performed when k = 20, 30,
or 40; l = 100; and m = 140. The particular numbers of
the constants were adopted to be consistent with epide-
miological data in Japan [5,16]. In this situation, the cumu-
lative IRCVD of the sample population is 0.01 events/year,
which corresponds to a moderate risk for CVD or that of
middle-aged Japanese men. These constants are influenced
by risk factors such as smoking and glucose and lipid pro-
files. Subjects with diabetes or previous CVD are out of
our scope because CVD risk assessment is different from
our estimation [5]. Effects of other medications such as
statin and aspirin are estimated independently from those
of antihypertensive medications [20].
The cumulative IRCVD was calculated by the definite
integral from the lowest to the highest SBP of the IRCVD
at each SBP level in the sample population [3]. The
population IRCVD was evaluated as the product of distri-
bution according to SBP multiplied by the cardiovascu-
lar event rate at each SBP (Figure 1).
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Where f(x)a n dP(x) represent probability density
function and IRCVD according to SBP, respectively.
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IRCVD after administration of antihypertensive
medications
In this simulation study, we assumed that IRCVD after the
interventions would gradually converge with IRCVD
directly calculated from the SBP levels after the interven-
tions. Similar to the estimates used in earlier simulation
studies [3,21], CVD risk estimates after interventions were
calculated by using a formula before interventions that
was based on the SBP level after interventions. Risk reduc-
tion in cardiovascular complications by antihypertensive
treatment is expected to reach ~50% within several years
[18]. Therefore, we estimated that a 50% of the decrease in
SBP by the two approaches would contribute to IRCVD
reduction in several years.
IRCVD after administration of antihypertensive medica-
tions
  
          


fx P x d x
fx Pxd x fx Pxg x s x
L
H
L
e
11
00 00
()
  
       


dx
fx Px s x d x
e
H
e
H
001,
Where e, g(x), and s(x)r e p r e s e n tt h eS B Pl e v e la tt h e
initial administration of antihypertensive medications,
the SBP-lowering effect of the antihypertensive medica-
tions and success rate of antihypertensive treatment.
Antihypertensive medications were applied to hyperten-
sive patients in the sample with an SBP > 140, 150, and
160 mm Hg. The consultation rate for medical care was
estimated as a function of SBP, and the SBP-lowering
effects of the antihypertensive medications were simu-
lated in several situations. In this simulation study,
beyond-BP effects that are expected in some antihyper-
tensive medications and in the non-pharmacological
treatment of the usual clinical settings were assumed to
be factored into the SBP-reducing values. Beyond-BP
effects in some antihypertensive medications were con-
sidered to be relatively small compared with BP lower-
i n gi np r e v e n t i n gC V D[ 2 0 ] .W ea d o p t e ds t e p w i s e
combination medications to control SBP to the target
level, if necessary, as the Japanese hypertension treat-
ment guidelines recommend, predominantly with an
angiotensin II receptor blocker and a calcium channel
blocker [22].
Antihypertensive treatment constitutes at least two of
the following major components: the consultation rate
with primary physicians after patients are diagnosed
with hypertension at the annual health check and the
achievement rate in lowering BP to the target SBP level.
However, few reports are available concerning these
components [23], especially in Japan [24]. Moreover, the
physician consultation rate for medical care after
patients are diagnosed with hypertension in an annual
health check program is seldom investigated in regional
settings. The Japanese government mandates primary
physicians to report the number of patients with certain
common diseases on 1 day every 3 years. The consulta-
tion rates are estimated from the ratio of the total num-
ber of outpatients who visited medical facilities on the
patient survey day to the total population of Japan
(http://www.mhlw.go.jp/toukei/saikin/hw/kanja/05/02-
02.html). Given these circumstances, we proposed a few
assumptive equations to calculate IRCVD on the basis of
primary healthcare settings and earlier epidemiological
investigations [18,25]. We adopted an exponential math-
ematical formula to estimate the consultation rate and
the success rate in order to produce a feasible calcula-
tion in combining the normal distributions of SBP
levels, considering that the consultation rate should get
closer to 100% if SBP raises [26]. First, the consultation
rate of primary physicians after the annual health check
program for metabolic syndrome is assumed to be
represented by the following equation: consultation rate
(patients who visited primary physicians/patients who
are diagnosed with hypertension in the annual health
Figure 1 Relationship between systolic blood pressure
(SBP) and cardiovascular event rate (IRCVD).I R CVD
=1
l
SBP m
k
exp    . The thick black, thin black, and thick gray lines
represent k = 20, 30, and 40, respectively, where l = 100 and m =
140. For example, when k = 20, the IRCVD is 0.0036/year, 0.01/year,
and approximately 0.027/year when SBP is 120, 140, and 160 mm
Hg, respectively, and corresponds to a moderate risk in the
Japanese Society of Hypertension 2009 guidelines.
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Page 3 of 9check) = 1-exp(-(SBP-a)*b) (a = an alarming SBP of 130,
140, and 150 mm Hg, above which patients should
be concerned about their BP; and b = an accessibility
factor to a primary physician of 0.05, 0.03, and 0.02)
(Figure 2a). The consultation rate has a large impact on
the size of the population (Figure 2b). The particular
numbers of the constants were adjusted to realistic
Japanese situations (approximately 20-30%) [5,24]. Con-
versely, the rate without consulting a medical doctor =
exp(- (SBP - a) * b). Second, the SBP-lowering effect of
antihypertensive medication is assumed by the following
equation: SBP-lowering effect = (SBP-c)*d (c = the tar-
get SBP level of 130, 140, and 150 mm Hg; d = adher-
ence for reaching the target SBP level of 0.6, 0.7, and
0.8) [22]. A primary physician’s compliance with hyper-
tension treatment guidelines [23] and a patient’sd r u g
adherence constitute important parts of factor “d” [27].
Antihypertensive medication is simulated as being
initiated from the following SBP levels: e = 140, 150,
and 160 mm Hg [28]. Earlier studies demonstrated vary-
ing levels of physician adherence to hypertension guide-
lines, which were usually disappointingly low. To cite a
case of hypertensive patients whose SBP is 160 mm Hg,
when k = 20, l = 100, and m = 140, the IRCVD before
intervention is approximately 0.027/year (Figure 1); with
an optimistic situation of a = 140 and b = 0.03, a con-
sultation rate of 0.45 (Figure 2a), and a realistic SBP-
lowering effect (c = 140, d = 0.7, and e = 150, or [160-
140] × 0.7 × 0.5 = 7 mm Hg), the IRCVD after antihyper-
tensive medications is approximately 0.019/year.
IRCVD after health promotion
IRCVD after heath promotion
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Where f0(x) and P0(x) represent the probability density
function and IRCVD of cardiovascular events before
intervention, respectively, and f1(x)a n dP1(x)r e p r e s e n t
the probability density function and IRCVD of cardiovas-
cular events after intervention, respectively. a and b
represent the SBP-lowering effect, including the other
cardiovascular risks and the success rate of health pro-
motion programs, respectively. We simulated the health
promotion program for metabolic syndrome as being
applied to the total population. The effects of the speci-
fic health promotion program on cardiovascular compli-
cations are assumed to be 5, 10, and 20 mm Hg when
they are represented as SBP-lowering effects in several
years. The PREMIER trial has recently reported that life-
style modifications for BP control (sodium reduction,
weight loss, and increased physical activity) decreased
10 mm Hg in SBP and 0.0002 events/year reduction in
heart attack rate by in middle-aged, healthy, untreated
individuals with prehypertension or stage I hypertension
[9]. A pilot non-randomized controlled study in Japan
has recently indicated that a 27-month community-
based lifestyle approach to CVD resulted in 1 mm Hg
and 3 mm Hg differences in SBP between the interven-
tion and control groups for men and women, respec-
tively [29].
The health promotion program has three support sys-
tems, stratified according to metabolic risk profiles: (1)
an affirmative support system to improve the effects of
metabolic syndrome continuously for 6 months (more
than three close contacts with health care nurses), (2) a
support system to motivate metabolic syndrome candi-
dates to improve their health conditions (two contacts
with health care nurses), and (3) a support system to
offer individual information for health promotion when
the results of the annual health check are sent. In the
simulation, we calculated the success rates of these stra-
tegies at three levels: (1) realistic, (2) optimistic, and (3)
ideal. The calculations in each scenario are summarized
in Table 1. The Japanese Ministry of Health, Labour
and Welfare has advocated a success rate of 10% by the
Figure 2 Relationship between systolic blood pressure (SBP)
and consultations. (a) SBP and primary physician consultation rate
of hypertensive patients. The consultation rate = 1-exp(-(SBP-a)×b)
(a = alarming SBP level, above which patients should be concerned;
b = the accessibility factor to a primary physician). The thick black
(a = 130, b = 0.05), thin black (a = 140, b = 0.03), and thick gray
(a = 150, b = 0.02) lines represent ideal, optimistic, and realistic
situations, respectively. (b) SBP and probability of consultation
with a primary physician. The probability equals the product of
the probability density in the sample population and the
consultation rate.
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Page 4 of 9end of fiscal year 2013 (http://www.niph.go.jp/soshiki/
jinzai/koroshoshiryo/tokutei/). To cite a case of hyper-
tensive patients whose SBP is 160 mm Hg, when we
promote the health program optimistically (a =1 0m m
Hg), the IRCVD after health promotion at the corre-
sponding SBP level (160 - 10 × 0.5 = 155 mmHg) is
0.021. The success rate is estimated as b = 0.275 in the
optimistic situation.
The comparison between the conventional BP-lower-
ing treatment and the health promotion program for
improving metabolic syndrome is based on the following
t w oi n d e x e s :t h er e d u c t i o n si nI R CVD by the two
approaches and the number of health checks (NHC)
needed to decrease one cardiovascular complication per
year in each approach.
NHC 
       
1
00 11 f x P x dx f x P x dx
L
H
L
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Where f0(x) and P0(x) represent the probability density
function and IRCVD before intervention, respectively,
and f1(x)a n dP1(x) represent the probability density
function and IRCVD after intervention, respectively. After
confirming the accuracy of the results by comparing the
authentic definite integral method and the numerical
analytical approach, we performed these calculations by
using numerical analysis with 1 mm Hg intervals.
Results
The cumulative risk reduction with traditional antihy-
pertensive medications is demonstrated in the represen-
tative combinations of several factors, such as a, b, c, d,
and e, when IRCVD is assumed to be an exponential
function, or Px
l
xm
k
( ) exp    
1 (Table 2). Figure 3
demonstrates that the relationship between SBP and
IRCVD is reduced by prescribing antihypertensive medi-
cations in virtual situations.
The cumulative risk reduction accompanied by the
health promotion program is calculated in the
representative combinations of several factors, such as a
and b (Table 3 and Figure 4).
The NHC to rescue one cardiovascular event per year
is much lower for antihypertensive medications than it
is for health promotions in corresponding virtual situa-
tions. For example, in the case of k = 20, l = 100, and m
= 140, if we prescribe antihypertensive medicines to
patients whose SBP is not less than 150, accessibility to
the medical office is 0.03 or the usual situation, the tar-
get SBP is set to 140 mm Hg, and the success rate is
0.7, ΔIRCVD and NHC are estimated at 9.99 × 10
-4 and
1001, respectively. In contrast, even if we can promote
the health program optimistically, participants reduce
their body weight (BW) by ~5 kg, and their risk reduc-
tion is estimated at a 10 mm Hg SBP-lowering effect,
IRCVD and NHC are estimated at 4.69 × 10
-4 and 2134,
respectively.
In Figure 3 and Figure 4, ΔIRCVD is shown as the sub-
tracted area of the IRCVD before and after the two
approaches. Below the SBP level at which antihyperten-
sive medications were prescribed,ΔIRCVD at each SBP
level is slightly higher in Figure 4 than in Figure 3.
However, above the SBP level at which antihypertensive
medications were prescribed, ΔIRCVD at each SBP level
is much higher in Figure 3 compared with the corre-
sponding simulation curves.
Discussion
Our success rate-oriented simulation demonstrates that
antihypertensive medications are more effective than
the health promotion program for improving metabolic
syndrome in reducing the risk of cardiovascular events.
This result suggests that primary physicians should
treat hypertensive patients whose SBP levels are not
less than 140 mm Hg with medications, as the tradi-
tional hypertensive guidelines recommend. Although
this simulation allows a substantial role for the health
promotion program in reducing cardiovascular events,
risk reduction with traditional antihypertensive medi-
cations is superior. The novelty of our simulation is in
Table 1 Success rate of health promotion programs
Support system to improve metabolic syndrome Indifferent to metabolic syndrome Σ
Affirmative campaign Motivating campaign Offering information
Realistic pattern 10 20 50 20 13.75
37.5 25 10 0
Optimistic pattern 10 20 50 20 27.5
75 50 20 0
Ideal pattern 10 20 50 20 50
100 75 50 0
The upper and lower numbers in each cell represent the proportion of candidates assigned to the corresponding program and its success rate. Σ in the right-
most column represents the total success rate, calculated as the sum of the products of the proportion of candidates assigned to the program multiplied by its
success rate.
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although we used several ambitious assumptions. The
consultation rate has a large impact on reducing cardi-
ovascular events through the prescription of antihyper-
tensive medications.
The population-based approach to the prevention of
cardiovascular events by improving metabolic syndrome
may be more unsatisfactory than expected for several
reasons: (1) The risk reduction of health promotion for
improving metabolic syndrome in CVD might be under-
estimated. We took the BP-lowering effect of health
promotion to improve metabolic syndrome into account
for reducing cardiovascular complications. The BP-low-
ering effect by reducing BW is estimated at 1 to 2 mm
Hg/kg BW loss [5,25,30]. The effect of the health pro-
motion program on lowering SBP is limited, and the
effect on reducing risk might be beyond what we antici-
pated [25,31-33]. The health promotion program can
reduce the risk of cardiovascular complications through
pathways without lowering BP. For example, weight loss
improves metabolic factors such as glucose and lipid
profiles [8,34], and physical activity can inhibit the pro-
duction of reactive oxygen species [35]. In addition, the
beneficial effects of the interaction between lowering BP
and metabolic factors in inhibiting cardiovascular events
may go beyond what we anticipated. (2) The risk of car-
diovascular events increases exponentially with SBP ele-
vation. For this assumption, the sum of the risk of
Table 2 Reduction in cardiovascular event rate by traditional antihypertensive medications in a hypothetical
population
k = 20 a = 130 mm Hg a = 140 mm Hg a = 150 mm Hg a = 160 mm Hg
b = 0.05 b = 0.03 b = 0.02 b = 0.01
c = 130 mm Hg c = 140 mm Hg c = 150 mm Hg c = 160 mm Hg
d = 0.8 d = 0.7 d = 0.6 d = 0.5
e = 140 mm Hg 2.33 × 10
-3
e = 150 mm Hg 2.08 × 10
-3 9.99 × 10
-4
e = 160 mm Hg 1.56 × 10
-3 8.46 × 10
-4 4.52 × 10
-4
e = 180 mm Hg 4.51 × 10
-4 3.02 × 10
-4 1.92 × 10
-4 6.64 × 10
-5
k = 30 a = 130 mm Hg a = 140 mm Hg A = 150 mm Hg a = 160 mm Hg
b = 0.05 b = 0.03 b = 0.02 b = 0.01
c = 130 mm Hg c = 140 mm Hg c = 150 mm Hg c = 160 mm Hg
d = 0.8 d = 0.7 d = 0.6 d = 0.5
e = 140 1.13 × 10
-3
e = 150 9.68 × 10
-4 4.24 × 10
-4
e = 160 6.74 × 10
-4 3.42 × 10
-4 1.76 × 10
-4
e = 180 1.58 × 10
-4 1.01 × 10
-4 6.26 × 10
-5 2.06 × 10
-5
k = 40 a = 130 mm Hg a = 140 mm Hg A = 150 mm Hg a = 160 mm Hg
b = 0.05 b = 0.03 b = 0.02 b = 0.01
c = 130 c = 140 c = 150 c = 160
d = 0.8 d = 0.7 d = 0.6 d = 0.5
e = 140 7.32 × 10
-4
e = 150 6.14 × 10
-4 2.58 × 10
-4
e = 160 4.11 × 10
-4 2.02 × 10
-4 1.02 × 10
-4
e = 180 8.66 × 10
-5 5.40 × 10
-5 3.31 × 10
-5 1.06 × 10
-5
Abbreviations: k = constant determining the slope of the exponential curve between systolic blood pressure and cardiovascular incidence rate; l = constant
related to absolute value of cardiovascular incidence rate of 100; m = constant determining the slope of the exponential curve to be e
0/l of 140; a = an alarming
SBP of 130, 140, 150, and 160 mm Hg, above which patients should be concerned about their BP; b = an accessibility factor to a primary physician of 0.05, 0.03,
0.02, and 0.01; c = the target SBP level of 130, 140, 150, and 160 mm Hg; d = adherence for reaching the target SBP level of 0.5, 0.6, 0.7, and 0.8; e = SBP level
of 140, 150, 160, or 180 mm Hg from which administration of antihypertensive medications was initiated.
Figure 3 Relationship between systolic blood pressure and
cardiovascular event rate before and after prescribing
traditional antihypertensive medications. The solid black, dotted
black (>160 mm Hg), dashed grey (>150 mm Hg), and dashed black
(>140 mm Hg) lines represent no antihypertensive treatment and
realistic, optimistic, and ideal antihypertensive treatments,
respectively. The area between the solid black line and the
corresponding line represents the reduction in the incidence rate of
cardiovascular events.
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Page 6 of 9cardiovascular complications at SBP levels of less than
140 mm Hg is small even when the slope of the curve
for the relationship between SBP and IRCVD is low. In
other words, BP is an excellent predictor of CVD, espe-
cially in Japan, where stroke has been more prevalent
than ischemic heart disease. Hypertension is a determi-
nant component in Japanese men with metabolic syn-
drome for predicting cardiovascular complications [36].
One criticism of our model is that the estimation of
both approaches may be too optimistic. Only a few
researchers have reported the consultation rate in a gen-
eral Japanese population [24].
Another assumption of our model relates to adher-
ence of the primary physician to the hypertensive
treatment guidelines and the patients’ adherence to
medication. The success rate of antihypertensive treat-
ment, according to the Japanese antihypertensive treat-
ment guidelines, is reported to be 30 to 60% [37,38].
W ea s s u m e dt h a tI R CVD after the interventions will
g r a d u a l l yc o n v e r g ew i t hI R CVD directly calculated from
the SBP levels after the interventions, as shown in
another simulation [21]. This estimation is based on
the guidelines and the evidence derived from large-
scale clinical investigations and long-term follow-up
studies [5,18,39].
One question about our model concerns what would
happen if traditional antihypertensive medications and
the health promotion program were administered con-
currently. If the effects of both approaches are indepen-
dent, then the overall effect of both approaches is the
difference between the sum and the product of each
approach. However, this assumption is too robust to
adopt because most hypertensive patients with meta-
bolic syndrome might be encouraged to lose weight in
the medical office of the outpatient department, the
usual clinical setting, not as part of a health promotion
approach offered by a health nurse. In addition, the suc-
cess rate of the health promotion program will decrease
if patients are satisfied with the reduction in SBP as a
result of taking antihypertensive medications. Most indi-
viduals are willing to accept only one approach at a
time [7]. These factors greatly interfere with the inde-
pendency of both approaches.
Another question relates to why we boldly assumed
the transfer of metabolic risk factors onto SBP levels.
There are few reports available that address how to
transfer metabolic risk factor onto SBP levels. The
estimation of the relationship between the SBP levels
and IRCVD is a key factor in assessing these issues. In
the simulation model, the absolute value of IRCVD
related to factor “l” does not influence the results of
the simulation. A sensitive question is whether tradi-
tional antihypertensive medications are more effective
if we restricted the subjects whose SBP levels are
within the high normal range (130-139 mm Hg) from
the model. The superiority of the medication would
become unclear in the high normal SBP range (data
not shown).
Many undefined issues in preventive medicine emerge
from this pioneer simulation study. In future, the con-
sultation rate and medication adherence in various
situations should be investigated vigorously. This study
indicates that the consultation rate has a tremendous
impact on IRCVD in a high-risk approach. We propose
that two components are related to the consultation
rate: awareness of hypertension and accessibility to med-
ical care. However, many other factors and relations
such as cost-effectiveness, economic status, and preven-
tive health information need to be explored.
Figure 4 Relationship between systolic blood pressure and
cardiovascular event rate before and after promoting health
promotion programs. The solid black, dotted grey, dashed black,
and dashed gray lines represent no health promotion program and
realistic, optimistic, and ideal health promotion programs,
respectively. The area between the solid black line and the
corresponding line represents the reduction in cardiovascular event
rates. The solid black line overlaps the dotted grey line considerably.
Table 3 Reduction in incidence rate of cardiovascular
events per year by the health promotion program in a
hypothetical population
k=2 0 a =2 0m mH g a =1 0m mH g a = 5 mm Hg
b ideal 1.35 × 10
-3 8.52 × 10
-4 4.92 × 10
-4
b optimistic 7.42 × 10
-4 4.69 × 10
-4 2.71 × 10
-4
b realistic 3.71 × 10
-4 2.34 × 10
-4 1.35 × 10
-4
k=3 0 a =2 0m mH g a =1 0m mH g a = 5 mm Hg
b ideal 8.40 × 10
-4 5.05 × 10
-4 2.90 × 10
-4
b optimistic 4.62 × 10
-4 2.78 × 10
-4 1.59 × 10
-4
b realistic 2.31 × 10
-4 1.39 × 10
-4 7.97 × 10
-5
k=4 0 a =2 0m mH g a =1 0m mH g a = 5 mm Hg
b ideal 6.31 × 10
-4 3.72 × 10
-4 2.16 × 10
-4
b optimistic 3.47 × 10
-4 2.05 × 10
-4 1.19 × 10
-4
b realistic 1.74 × 10
-4 1.02 × 10
-4 5.93 × 10
-5
Abbreviations: k = constant determining the slope of the exponential curve
between systolic blood pressure and cardiovascular incidence rate; l =
constant related to absolute value of cardiovascular incidence rate of 100; m
= constant determining the slope of the exponential curve to be e
0/l of 140;
a = SBP-lowering effect (mm Hg), including the other cardiovascular risks; b =
success rate of health promotion program.
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Page 7 of 9Conclusions
A traditional approach of using antihypertensive treatment
is superior to the health promotion approach for improv-
ing metabolic syndrome by reducing the risk of cardiovas-
cular events in a sample population of middle-aged
Japanese men. However, the health promotion approach
also has a substantial impact on reducing cardiovascular
events if success rate is satisfactory in this group.
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